Belldegrun Arie 13D and 13G filings for Allogene Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-13 4:31 pm Purchase |
2024-12-31 | 13G | Allogene Therapeutics, Inc. ALLO |
Belldegrun Arie | 12,393,567 5.800% |
2,497,664 (+25.24%) |
Filing |
| 2024-02-14 4:36 pm Purchase |
2023-12-31 | 13G | Allogene Therapeutics, Inc. ALLO |
Belldegrun Arie | 9,895,903 5.800% |
1,037,042 (+11.71%) |
Filing |
| 2023-02-13 4:31 pm Purchase |
2022-12-31 | 13G | Allogene Therapeutics, Inc. ALLO |
Belldegrun Arie | 8,858,861 6.100% |
1,655,613 (+22.98%) |
Filing |
| 2022-02-14 3:36 pm Purchase |
2021-12-31 | 13G | Allogene Therapeutics, Inc. ALLO |
Belldegrun Arie | 7,203,248 5.000% |
708,755 (+10.91%) |
Filing |
| 2021-02-12 2:32 pm Sale |
2020-12-31 | 13G | Allogene Therapeutics, Inc. ALLO |
Belldegrun Arie | 6,494,493 4.600% |
-859,507 (-11.69%) |
Filing |